Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Critical Outcome Technologies, Inc. (COTQF : OTC)

• Company Description    Cotinga Pharmaceuticals Inc. is a clinical-stage pharmaceutical company which uses proprietary artificial intelligence technologies to develop innovative therapies to treat a wide spectrum of cancers. The Company's CHEMSAS(R) platform evaluates biological activity from molecular structures, allowing the Company to build a pipeline of potential drug candidates with predictive accuracy and expediency when compared to traditional development methods. Cotinga Pharmaceuticals Inc., formerly known as Critical Outcome Technologies Inc., is based in Boston, Massachusetts. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.00 Daily Weekly Monthly 20 Day Moving Average: shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 52 Week High: $ 52 Week Low: $ Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week % % 12 Week % % Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 127 Main Street - Boston,MA 02129 USA ph: 860-798-0816 fax: 519-858-5179 ir@cotingapharma.com http://coti.theyatesnetwork.com

• General Corporate Information    Officers Alison Silva - President and Chief Executive Officer John C. Drake - Chairman Gene Kelly - Chief Financial Officer Kowthar Salim - Vice President John Yoo - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 22164W105 SIC: 2834 Fiscal Year Fiscal Year End: April Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: Most Recent Split Date: 6.00 (0.10:1) Beta: Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 04/30/25 - - 01/31/25 - - 10/31/24 - - ROA 04/30/25 - - 01/31/25 - - 10/31/24 - - Current Ratio 04/30/25 - - 01/31/25 - - 10/31/24 - - Quick Ratio 04/30/25 - - 01/31/25 - - 10/31/24 - - Operating Margin 04/30/25 - - 01/31/25 - - 10/31/24 - - Net Margin 04/30/25 - - 01/31/25 - - 10/31/24 - - Pre-Tax Margin 04/30/25 - - 01/31/25 - - 10/31/24 - - Book Value 04/30/25 - - 01/31/25 - - 10/31/24 - - Inventory Turnover 04/30/25 - - 01/31/25 - - 10/31/24 - - Debt-to-Equity 04/30/25 - - 01/31/25 - - 10/31/24 - - Debt-to-Capital 04/30/25 - - 01/31/25 - - 10/31/24 - -

Powered by Zacks Investment Research ©